Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 antibody rituximab. In recent years, new antibodie...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncoimmunology
Main Authors: Elias, Shlomo, Kahlon, Shira, Kotzur, Rebecca, Kaynan, Noah, Mandelboim, Ofer
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2018
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980409/
https://ncbi.nlm.nih.gov/pubmed/29872553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1428158
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker